http://www.fpnotebook.com/
AdalimumabAka: Humira
- See Also
- Indications
- Severe active Rheumatoid Arthritis refractory to DMARDs
- Contraindications
- Mechanism: Monoclonal Antibody
- Human antitumor Necrosis Factor alpha
- Similar to Infliximab and Etanercept
- Dosing
- Every other week: 40 mg SC
- Adverse Effects
- Immunosuppression
- Use caution in any patient prone to infection
- Headache
- Rash
- Hypertension
- Hyperlipidemia
- Injection site inflammation
- Gastrointestinal upset
- Immunosuppression
- Cost
- Two 40 mg vials: $1200 (in 2003)
- References
- (2003) Lexi-Comp Drug Database
adalimumab (C1122087) | |
|---|---|
| Concepts | Amino Acid, Peptide, or Protein (T116) , Pharmacologic Substance (T121) , Immunologic Factor (T129) |
| MSH | C453439 |
| English | adalimumab, ADALIMUMAB PREPARATION, D2E7 antibody |
| Spanish | adalimumab |
| Parent Concepts | Immunosuppressive Agents (C0021081), Other antirheumatics (C0973578), Unclassified Ingredients (C1372954), Antirheumatic Agents (C0003191), Monoclonal antibody preparation (C1298636), Anti-tumor necrosis factor alpha drug (C1562242), Tumor Necrosis Factor (TNF) Inhibitors (C1579324) |
| Sources | MSH, NCI, NDFRT, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
Humira (C1171255) | |
|---|---|
| Concepts | Amino Acid, Peptide, or Protein (T116) , Pharmacologic Substance (T121) , Immunologic Factor (T129) |
| MSH | C453439 |
| English | Abbott brand of adalimumab, Humira |
| Sources | MSH, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |